Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Alofanib (RPT835) 是一种高效和选择性的成纤维细胞生长因子受体2的变构抑制剂,具有抗癌和抗血管生成活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 313 | 现货 | ||
5 mg | ¥ 747 | 现货 | ||
10 mg | ¥ 1,080 | 现货 | ||
25 mg | ¥ 2,160 | 现货 | ||
50 mg | ¥ 3,230 | 现货 | ||
100 mg | ¥ 4,770 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 822 | 现货 |
产品描述 | Alofanib (RPT835) is a selective allosteric inhibitor of FGFR2 and has a dramatic inhibitory effect on FGF2-induced phosphorylation of FRS2a in KATO III cells (IC50 <10 nM). It has no direct effect on FGF2-dependent FGFR1 and FGFR3 phosphorylation levels in either cell lines and no effects on FGF2-FGFR2 binding. |
靶点活性 | FGFR2:<10 nM |
体外活性 | In SKOV3 cell line, Alofanib induces mainly apoptosis with cleavage of caspase 3, PARP and Bcl-2. It has a low cytotoxic effect on ovarian cancer cells [1]. Alofanib inhibits phosphorylation of FRS2α with the IC50 values of 7 and 9 nmol/l in cancer cells expressing different FGFR2 isoforms. In a panel of four cell lines representing several tumor types (triple-negative breast cancer, melanoma, and ovarian cancer), alofanib inhibits FGF-mediated proliferation with 50% growth inhibition (GI50) values of 16-370 nmol/l. Alofanib dose-dependently inhibits the proliferation and migration of human and mouse endothelial cells (GI50: 11-58 nmol/l) compared with brivanib and bevacizumab [2]. |
体内活性 | Alofanib (i.v.) significantly in a dose-dependent manner potentiated the efficiency of the combination of paclitaxel and carboplatin. Alofanib suppresses angiogenesis in the ovarian cancer mouse model[1]. In an FGFR-driven human tumor xenograft model, oral administration of alofanib is well tolerated and results in potent antitumor activity[2]. |
细胞实验 | SKOV3 cells were treated with alofanib (10, 100, and 1000 μM) for 72 h and whole-cell lysates were immunoblotted. |
别名 | RPT835 |
分子量 | 413.4 |
分子式 | C19H15N3O6S |
CAS No. | 1612888-66-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
DMSO: 55 mg/mL (133.04 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.419 mL | 12.0948 mL | 24.1896 mL | 60.4741 mL |
5 mM | 0.4838 mL | 2.419 mL | 4.8379 mL | 12.0948 mL | |
10 mM | 0.2419 mL | 1.2095 mL | 2.419 mL | 6.0474 mL | |
20 mM | 0.1209 mL | 0.6047 mL | 1.2095 mL | 3.0237 mL | |
50 mM | 0.0484 mL | 0.2419 mL | 0.4838 mL | 1.2095 mL | |
100 mM | 0.0242 mL | 0.1209 mL | 0.2419 mL | 0.6047 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Alofanib 1612888-66-0 Angiogenesis Apoptosis Tyrosine Kinase/Adaptors FGFR RPT 835 Inhibitor inhibit RPT-835 RPT835 Fibroblast growth factor receptor inhibitor